Atrial fibrillation: Flec-SL trial proves efficacy of short-term antiarrhythmic drug treatment
Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF.
In most cases, AF can be treated successfully by an electrical cardioversion. Unfortunately, in the majority of patients, AF recurs during the first days or weeks after cardioversion. This is due to electrical reorganisation processes in the atria which contribute to recurrent AF in patients. Antiarrhythmic drug treatment can reverse parts of the electrical remodeling process and prevent recurrences of AF.
It is well-known that the atria recover from electrical remodeling within four weeks after cardioversion. Beyond this period, AF relapses occur much less frequently, suggesting that antiarrhythmic drug treatment might be needed only in the first four weeks after cardioversion. However, a long-term treatment is usually applied. A shorter duration of drug treatment (therapeutic de-escalation) would make therapy safer, cheaper, and applicable for more patients.
AFNET, the German Competence Network on Atrial Fibrillation, therefore performed a randomized clinical trial to investigate whether a short-term antiarrhythmic drug treatment for the duration of four weeks after cardioversion could prevent recurrences of AF as effectively as the usual long-term treatment ("non inferiority trial"). This was assessed using the approved drug flecainide. The Flec-SL (flecainide short long) trial was conducted by AFNET under the direction of principal investigators Prof. Paulus Kirchhof, Birmingham UK and Muenster, Germany, and Prof. Guenter Breithardt, Muenster, Germany, both prominent members of EHRA, the European Heart Rhythm Association of the European Society of Cardiology (ESC).
Between May 2007 and March 2010, more than 600 patients were enrolled in the study at 44 centres in Germany. Patients were randomised to different groups where they were treated with flecainide for either four weeks or six months. Additionally, there was a control group without antiarrhythmic drug treatment. In all study patients, recurrences of AF were assessed by daily trans-telephonic ECGs within the observation period of six months.
Analysis of the study data reveals: antiarrhythmic long-term treatment is superior to short-term treatment, but also the four-week short-term treatment was able to prevent recurrences of AF: AF relapses occurred in 120 of 261 patients receiving short-term treatment and only in 103 of 263 patients receiving long-term treatment. At the end of the study, short-term therapy reached about 80 percent of the effect of long-term therapy.
Principal investigator Prof. Kirchhof, is sure that these findings have implications for clinical routine: "Although antiarrhythmic short-term treatment is inferior to long-term treatment, it will be useful in selected patients. Short-term treatment should be considered for AF patients who are at increased risk for complications or adverse effects. We hope that the new results find their way into guidelines for the management of AF."
Provided by European Society of Cardiology
- Atrial fibrillation treatment with catheter shows better results than drug therapy Jan 27, 2010 | not rated yet | 0
- The Medical Minute: Atrial Fibrillation -- What is It? Oct 06, 2011 | not rated yet | 0
- Study examines comparative effectiveness of rhythm control vs. rate control drug treatment Jun 04, 2012 | not rated yet | 0
- Kidney disease increases the risk of stroke in patients Mar 04, 2009 | not rated yet | 0
- UK doctors still undertreating atrial fibrillation - major risk factor for stroke Oct 13, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
what is the distance traveled
3 hours ago Hi. I have newly started to study mechanical physics. based on study, I conduct a simple experiment. But unfortunately i am unable apply the laws in...
Image of a Convex Lens Cut in Half Horizontally
7 hours ago Hello everyone, A friend of mine came up with this question in class and I really do not have a good answer. Suppose you have a convex lens...
Ray tracing throught optical system of thick lenses
7 hours ago Can you advise me a free software that allow to draw rays passed throught system of thick lenses (preferable in 3D)?
Faraday's law on circular wire
8 hours ago In my examples on Faraday's law in my book, they use a drawing of a magnet approaching a circular wire. The changing magnetic flux then induces an...
Specific Exergy vs Specific Flow Exergy
9 hours ago I'm having some difficulty understanding exactly what the difference between the definitions of these values are. As I understand it, in terms of...
The Durability of Bone: Long Falls
18 hours ago I am doing a paper on the physics in Valve's Portal and got interested in the "Long Fall Boots" that prevent any damage no matter how far you fall. I...
- More from Physics Forums - Classical Physics
More news stories
Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.
Cardiology 4 hours ago | not rated yet | 0
Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...
Cardiology 6 hours ago | not rated yet | 0
Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...
Cardiology 6 hours ago | not rated yet | 0
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial ...
Cardiology 6 hours ago | not rated yet | 0
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...
Cardiology 22 hours ago | 5 / 5 (1) | 0
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...
35 minutes ago | not rated yet | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
14 minutes ago | not rated yet | 0 |
A man who had contracted the coronavirus has died in Saudi Arabia, raising the death toll in the kingdom from the SARS-like virus to 17, the health ministry announced on its website on Wednesday.
8 minutes ago | not rated yet | 0
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
7 minutes ago | not rated yet | 0
What effect does a father's depression have on his young son or daughter? When fathers report a high level of emotional intimacy in their marriage, their children benefit, said a University of Illinois study.
40 minutes ago | not rated yet | 0
Johns Hopkins researchers report that hospitals may be reaping enormous income for patients whose hospital stays are complicated by preventable bloodstream infections contracted in their intensive care units.
36 minutes ago | not rated yet | 0